4/A: Ionis Pharma CSO Corrects Erroneous Stock Transactions

Ionis Pharmaceuticals' Chief Scientific Officer, C. Frank Bennett, filed an amended Form 4 to correct and reverse previously reported erroneous stock sales and option exercises.

Summary

• C. Frank Bennett, EVP, Chief Scientific Officer of Ionis Pharmaceuticals Inc. (IONS), filed an amended Form 4 (Form 4/A).
• The amendment corrects an erroneous report from February 4, 2026, which incorrectly stated the sale of 20,000 shares of common stock and the exercise of 65,089 stock options.
• These erroneous transactions were subsequently reversed on February 12, 2026.
• Following the reversal, Mr. Bennett beneficially owns 100,293 shares of common stock as of February 12, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While an error occurred, it was promptly corrected, maintaining the insider's beneficial ownership and transparency.

Positives

• The erroneous transactions, which would have reduced insider ownership, were fully reversed, maintaining the insider's stake.
• C. Frank Bennett's beneficial ownership of 100,293 shares remains intact, indicating continued alignment with shareholder interests.

Negatives

• An administrative error led to the incorrect reporting of insider transactions, potentially causing temporary confusion among investors.

Future Outlook

No future outlook or guidance is provided in this administrative filing.

Industry Context

StockSavvy.ai notes that Form 4/A filings are common for correcting administrative errors in insider transaction reports, and this specific filing does not indicate any broader industry trends or competitive shifts.

Comparison to Industry Standards

• This filing is a standard correction for an insider transaction report. There are no specific comparable companies or projects to benchmark against, as it pertains to an individual's stock ownership correction rather than operational or financial performance.

Stakeholder Impact

• Shareholders: Provides clarity on insider ownership, correcting a previous misstatement and ensuring accurate disclosure.
• Management: Demonstrates commitment to accurate regulatory reporting and transparency.

Key Dates

Recommendation

This Form 4/A filing is purely administrative, correcting an erroneous insider transaction report. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The correction ensures transparency regarding insider ownership, which is a neutral event for the stock's fundamental value.

Keywords

Ionis Pharmaceuticals, IONS, Form 4/A, Insider Trading, Stock Ownership, Beneficial Ownership, C. Frank Bennett, SEC Filing, Amendment, Stock Options